drugset / Trial / NCT00523458
A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
RandomizedParallel-groupOpen-labelTreatment
Summary
Because drugs used to treat TB can reduce the amount of the anti-HIV drugs that reach the sites where the virus is located, this study is designed to see whether it is necessary to use higher doses of antiviral (anti-HIV) drugs while patients are receiving therapy with rifampin, one of the drugs commonly used to treat TB. Participants will be assigned to one of 4 arms (see below) and will be followed during the time when they are receiving both treatments.
Timeline
- Start
- 2007-07
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Efavirenz | Other / unclassified | 800 mg | — |
| Subject | Nevirapine | Small molecule | 200 mg | — |
| Subject | Nevirapine | Small molecule | 400 mg | — |